Two Sigma Advisers
ATYR

Two Sigma Advisers’s aTyr Pharma ATYR Stock Holding History

Two Sigma Advisers’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-841,350
Closed -$659K – 2255
2025
Q4 		$659K Buy
+841,350
New +$690K ﹤0.01% 1676
2025
Q1 		– Sell
-12,250
Closed -$44.3K – 2613
2024
Q4 		$44.3K Sell
12,250
-66,100
-84% -$200K ﹤0.01% 2290
2024
Q3 		$138K Sell
78,350
-17,500
-18% -$31.8K ﹤0.01% 2132
2024
Q2 		$150K Sell
95,850
-46,500
-33% -$80.9K ﹤0.01% 2270
2024
Q1 		$278K Sell
142,350
-5,400
-4% -$9.42K ﹤0.01% 2097
2023
Q4 		$208K Sell
147,750
-41,500
-22% -$53.2K ﹤0.01% 2218
2023
Q3 		$299K Sell
189,250
-189,600
-50% -$351K ﹤0.01% 1979
2023
Q2 		$818K Buy
378,850
+225,400
+147% +$492K ﹤0.01% 1610
2023
Q1 		$322K Sell
153,450
-2,700
-2% -$5.92K ﹤0.01% 2110
2022
Q4 		$342K Sell
156,150
-27,000
-15% -$63.7K ﹤0.01% 2022
2022
Q3 		$549K Sell
183,150
-800
-0.4% -$2.68K ﹤0.01% 1806
2022
Q2 		$521K Sell
183,950
-13,600
-7% -$49.2K ﹤0.01% 1905
2022
Q1 		$1.06M Sell
197,550
-189,802
-49% -$1.08M ﹤0.01% 1608
2021
Q4 		$2.89M Sell
387,352
-95,098
-20% -$794K 0.01% 1010
2021
Q3 		$4.38M Buy
482,450
+362,500
+302% +$2.17M 0.01% 856
2021
Q2 		$585K Buy
119,950
+105,850
+751% +$451K ﹤0.01% 1873
2021
Q1 		$63K Sell
14,100
-70,850
-83% -$333K ﹤0.01% 2486
2020
Q4 		$330K Sell
84,950
-83,300
-50% -$305K ﹤0.01% 2016
2020
Q3 		$543K Buy
168,250
+87,300
+108% +$358K ﹤0.01% 1788
2020
Q2 		$359K Buy
80,950
+44,600
+123% +$162K ﹤0.01% 2043
2020
Q1 		$102K Buy
+36,350
New +$157K ﹤0.01% 2298
2019
Q3 		– Sell
-850
Closed -$4K – 2419
2019
Q2 		$4K Hold
850
– – ﹤0.01% 2292
2019
Q1 		$7K Hold
850
– – ﹤0.01% 2271
2018
Q4 		$6K Buy
850
+14
+2% +$117 ﹤0.01% 2330
2018
Q3 		$10K Buy
+836
New +$9.15K ﹤0.01% 2204

Other funds holding ATYR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Two Sigma Advisers's ATYR Position: Q1 2026 in Review

Two Sigma Advisers sold out of aTyr Pharma (ATYR) in Q1 2026, closing a stake of 841,350 shares — an estimated $659K sold.

Two Sigma Advisers first reported a position in ATYR in Q3 2018 and held it in 25 quarters. The position peaked at $4.38M in Q3 2021. 111 funds tracked by Wall St. Rank hold ATYR as of Q1 2026.

  • Two Sigma Advisers reported no remaining aTyr Pharma position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 841,350 aTyr Pharma shares in Q1 2026, an estimated $659K.
  • Two Sigma Advisers first reported a position in aTyr Pharma in Q3 2018 and held it in 25 quarters.
  • Two Sigma Advisers's aTyr Pharma position peaked at $4.38M in Q3 2021.
  • 111 funds tracked by Wall St. Rank held aTyr Pharma as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.